



Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

To the Editor:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic has attracted interest because of its global rapid spread, clinical severity, high mortality rate and capacity to overwhelm healthcare systems [1, 2]. SARS-CoV-2 transmission occurs mainly through droplets, although surface contamination contributes and debate continues on aerosol transmission [3–5].

The disease is usually characterised by initial signs and symptoms [4–9] similar to those of related viral infections (*e.g.* influenza, SARS, Middle East respiratory syndrome) and tuberculosis (TB), although prognosis and complications sometimes differ. Experience with concomitant TB and COVID-19 is extremely limited.

One case–control study of COVID-19 patients with interferon- γ release assay-confirmed TB infection [10] and a single case of TB with COVID-19 have been submitted to, but not yet published in, peer-reviewed journals [11]. In a recent analysis of 1217 consecutive respiratory specimens collected from COVID-19 patients (*Mycobacterium tuberculosis* was not tested), the authors concluded that higher rates of co-infection between SARS-CoV-2 and other respiratory pathogens can be expected [12].

The present study describes the first-ever global cohort of current or former TB patients (post-TB treatment sequelae) with COVID-19, recruited by the Global Tuberculosis Network (GTN) in eight countries and three continents. No analysis for determinants of outcome was attempted.

The study is nested within the GTN project monitoring adverse drug reactions [13, 14] for which the coordinating centre has an ethics committee approval, alongside ethics clearance from participating centres according to respective national regulation [13, 14]. A specific nested database was created in collaboration with the eight countries reporting patients with TB and COVID-19; the remaining countries had not yet observed COVID-19 in their patients at the time this manuscript was written.

Continuous variables, if not otherwise specified, are presented as medians with interquartile ranges.

Overall, 49 consecutive patients with current or former TB and COVID-19 from 26 centres in Belgium ($n=1$), Brazil (Porto Alegre, Rio Grande do Sul State; $n=1$), France ($n=12$), Italy ($n=17$), Russia (Moscow Region; $n=6$), Singapore ($n=1$), Spain ($n=10$) and Switzerland (Vaud Canton; $n=1$) were recruited (dataset updated as of 25 April, 2020) (table 1).

The first onset of COVID-19 in the cohort was observed in an Italian patient with TB sequelae on 12 March, 2020 (symptoms from 6 March).

Of 49 patients, 26 (53.0%) had TB before COVID-19, 14 (28.5%) had COVID-19 first and nine (18.3%) had both diseases diagnosed within the same week (four on the same day).

42 (85.7%) patients had active TB (median age 45.5 (28.0–63.0) years) and seven (14.3%) had post-TB treatment sequelae (median age 69.0 (66.0–70.0) years; $p=0.01$); the patients with TB sequelae (from five centres in Italy, Singapore, Spain and Switzerland) were cured 8.2 (2.7–44.3) years earlier.

Overall, 26/49 (53.1%) patients were migrants, 15/48 (31.3%) unemployed, and 2/48 (4.1%) healthcare workers (medical doctor and radiology technician).

46 (93.9%) patients had confirmed SARS-CoV-2 infection and three other patients (6.1%) had chest high-resolution computed tomography (HRCT) highly suggestive of COVID-19 related pneumonia (bilateral ground glass opacities) [15].



@ERSpublications

Diagnostic, treatment and outcome details of 49 COVID-19 patients with concurrent or previous tuberculosis from 8 countries show varied clinical profiles <https://bit.ly/369ZGGu>

Cite this article as: Tadolini M, Codecasa LR, García-García J-M, *et al.* Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. *Eur Respir J* 2020; 56: 2001398 [<https://doi.org/10.1183/13993003.01398-2020>].

TABLE 1 Demographic, epidemiological and clinical characteristics of a cohort of 49 tuberculosis (TB) patients with coronavirus disease 2019 (COVID-19)

Variable	
Age years	48 [32–69]
Male	40/49 [81.6%]
Migrant status	26/49 [53.1%]
Occupation	
Employed	14/48 [29.2%]
Unemployed	15/48 [31.3%]
Retired	14/48 [29.2%]
Student	5/48 [10.4%]
BCG vaccination	19/30 [63.3%]
COPD/asthma	8/47 [17.0%]
Diabetes mellitus	8/49 [16.3%]
HIV infection	6/48 [12.5%]
Renal failure	5/49 [10.2%]
Liver disease	7/49 [14.3%]
Alcohol abuse[#]	10/49 [20.4%]
Smoking[¶]	20/49 [40.8%]
Drug abuse	4/47 [8.5%]
TB	
Previous history of TB	13/46 [28.3%]
Site	
Pulmonary TB only	36/49 [73.5%]
Extrapulmonary TB only	1/49 [2.0%]
Pulmonary TB/extrapulmonary TB (>1 site possible)	12/49 [24.5%]
Site of extrapulmonary TB	
Bone	2/13 [15.4%]
Lymphadenitis	2/13 [15.4%]
Pleural	2/13 [15.4%]
Central nervous system	1/13 [7.7%]
Laryngeal	1/13 [7.7%]
Gastrointestinal	1/13 [7.7%]
Peritonitis+lymphadenitis+pleural+bone	1/13 [7.7%]
Genitourinary+lymphadenitis	1/13 [7.7%]
Central nervous system+lymphadenitis	1/13 [7.7%]
Bone+joint+spondylodiscitis (T5-T11)+paravertebral abscesses	1/13 [7.7%]
Radiological involvement	
Unilateral cavitary lesions	10/48 [20.8%]
Bilateral cavitary lesions	13/48 [27.1%]
Bilateral infiltrates (no cavities)	9/48 [18.8%]
Unilateral infiltrates	16/48 [33.3%]
Microbiology	
Sputum culture confirmation	22/49 [44.9%] (+8 sputum culture ongoing)
NAAT confirmation	13/49 [26.5%]
Sputum smear positive	9/49 [18.4%]
Not available	5/49 [10.2%]
Drug resistance	
Resistant	8/45 [17.8%] (4 MDR-TB)
Sensitive	37/45 [82.2%]
Treatment outcome	
Cured	6/49 [12.2%]
Completed	1/49 [2.0%]
On treatment	37/49 [75.5%]
Died ⁺	5/49 [10.2%]
Lost to follow-up	0
Failure	0
COVID-19	
Symptoms	
Asymptomatic	5/48 [10.4%]
Symptomatic	43/48 [89.6%]

Continued

TABLE 1 Continued

Variable

Imaging	
Typical (bilateral ground glass opacities) HRCT picture	21/44 (47.7%)
Treatment outcome	
Resolved	18/49 (36.7%)
Still on treatment	25/49 (51.0%)
Died (at any date)*	6/49 (12.3%)

Data are presented as number/total number of patients for whom data are available (%) or median (interquartile range). #: ≥ 14 drinks per week in men or ≥ 7 drinks per week in women; †: current or ex-smoker; *: according to the criteria for cohort analysis of treatment results the number of patients who died during anti-TB treatment is five, but the total number of deaths is six, as one patient with post-TB treatment sequelae died after being cured for TB. BCG: bacillus Calmette–Guérin; NAAT: nucleic acid amplification test; MDR-TB: multidrug-resistant tuberculosis; HRCT: high-resolution computed tomography.

48 patients had pulmonary TB (one caused by *Mycobacterium bovis*).

37 patients had drug-susceptible (or were treated with the standard first-line regimen for new cases) and eight had drug-resistant TB (and were treated with second-line drugs).

Of the 14 non-clustered patients with COVID-19 diagnosis preceding TB, a child of Gambian origin (3 months old) had SARS-CoV-2 identified 3 days before TB diagnosis although TB was probably pre-existing (pulmonary and extra-pulmonary TB, meningitis). The child is continuing anti-TB treatment and has now recovered from COVID-19. Altogether the diagnosis of COVID-19 preceded that of TB by a median (range) time of 4 (2–10) days.

Those 14 patients, managed in nine centres (in France, Italy, Russia, Spain) were young (median age 33 (26.0–46.0) years); 11/14 (78.5%) were migrants.

Of the 19 patients undergoing anti-TB treatment, the diagnosis of COVID-19 was made during month 1–2 for 10 (52.6%), month 3–4 for three (15.7%), month 4–6 for three (15.7%) and after 6 months for three (15.7%) patients.

Signs and symptoms attributed to COVID-19 included (in different combinations) fever (32/48, 81.2%), dry cough (27/48, 56.2%) and dyspnoea (17/48, 35.4%).

Radiological information was available for 48/49 (98.0%) patients: 23 (47.9%) presented cavities (table 1).

21 patients manifested a typical HRCT COVID-19 pattern (bilateral ground glass opacities), whereas 23 had different patterns at HRCT or chest radiography essentially reporting TB-related lesions (infiltrates, consolidations, cavities, etc.) and five were not studied during the course of COVID-19 disease.

43 (87.8%) patients were hospitalised and, provisionally, the overall median (interquartile range) number of hospital admission days was 15 (8–27). Six patients needed noninvasive ventilation and 14 oxygen supply.

Medication for COVID-19 was reported for 28 patients in all countries except Belgium and Brazil (which had a single case each): 22 (78.6%) received, in different combinations, hydroxychloroquine, 12 (42.9%) received an anti-HIV protease inhibitor (i.e. lopinavir/ritonavir, darunavir/cobicistat), seven (25.0%) patients received azithromycin, and one (3.6%) patient received other drugs (i.e. enoxaparin and N-acetyl-cysteine (NAC)). 17 (60.8%) patients received monotherapy (i.e. 11 hydroxychloroquine, five lopinavir/ritonavir and one azithromycin), nine (32.1%) received a combination of two drugs (i.e. five hydroxychloroquine and protease inhibitor; four hydroxychloroquine plus azithromycin), two (7.1%) received three or more drugs (i.e. one hydroxychloroquine, lopinavir/ritonavir and azithromycin; one hydroxychloroquine, lopinavir/ritonavir and azithromycin, enoxaparin and NAC).

The case fatality rate was high (6/49, 12.3%); five of these six were >60 years old and all of them had at least one comorbidity. Given the small number of deaths, larger studies are necessary.

This preliminary analysis suggests that:

- 1) In 19/49 (38.8%) patients, COVID-19 appeared during anti-TB treatment and limited or no protection against COVID-19 might have favoured SARS-CoV-2 infection (which affected two healthcare workers).

- 2) The diagnosis of TB and COVID-19 was done simultaneously or within 7 days in nine patients, posing differential diagnosis challenges, suggesting that clinical assessments to investigate COVID-19 (e.g. clinical picture, HRCT) facilitated the identification of (a probably pre-existing) TB. Any contribution of COVID-19 to TB pathogenesis cannot be excluded or confirmed.
- 3) Although the diagnosis of COVID-19 preceded that of TB in 14 patients, larger studies are needed to understand any role played by SARS-CoV-2 in the progression of TB infection to disease. Given that up to a quarter of the population in some of the regions studied are latently infected, SARS-CoV-2 infection might boost the development of active TB in the coming months [10]. As we do not include individuals with latent TB infection followed up over time, we cannot report on the potential contribution of COVID-19 towards development of active disease. Probably, an overlap of signs/symptoms of COVID-19 and TB occurred, and COVID-19 was diagnosed earlier because of a higher index of suspicion, while TB may have been previously present. Or, differently, COVID brought to clinical evaluation/diagnostic assessment TB patients at an earlier stage of disease, before the occurrence of TB-related symptoms.
- 4) In seven cases, COVID-19 occurred in patients with TB sequelae. They were older than patients under anti-TB treatment and presented higher (although not statistically significant) mortality. All but one had comorbidities (four COPD; one HIV co-infection plus liver and kidney diseases, hypertension and cancer present in different combinations). They presented unilateral or bilateral radiological sequelae of previous infiltrates (four patients) or cavities (three patients). Larger numbers are necessary to further understand the role played by TB sequelae.
- 5) The impact on the healthcare system (days of admission, intensive care unit beds, etc.) was relevant, and will deserve further evaluation.
- 6) The information on BCG (bacillus Calmette–Guérin) vaccination is modest (30 patients with information, 19 previously vaccinated in all eight countries) and no significant elements can be provided to the ongoing debate on its protective role.
- 7) We presently have no data on drug–drug interactions.

This is, to our knowledge, the first published cohort of patients with active TB and COVID-19. Our study represents a “snapshot” of a cohort of patients at different stages of disease. No attempt was made to obtain representation of the larger universe of patients with both diseases and the small sample size precludes an analysis of risk factors. We cannot exclude that some findings have a casual origin.

The information available on the patients recently admitted was accurate, but some details on previous TB were incomplete, and some examinations were not performed either because the patients refused or the patients’ condition was too severe. Although case reporting is comprehensive in the countries/regions covered by GTN, the study reflects the initial stages of the COVID-19 epidemic only, and representative longitudinal observations will be necessary to evaluate the interactions between COVID-19 and TB.

We believe that this descriptive research can motivate larger studies to enable analyses of interactions and determinants of outcomes in patients with both diseases. The study will continue to follow-up the patients and accrue more records. We therefore invite interested clinicians and programmes to contact the corresponding author and help improve the understanding of how to optimise care for these patients.

Marina Tadolini^{1,44}, Luigi Ruffo Codecasa^{2,44}, José-María García-García³, François-Xavier Blanc⁴, Sergey Borisov⁵, Jan-Willem Alffenaar^{6,7,8}, Claire Andréjak⁹, Pierre Bachez¹⁰, Pierre-Alexandre Bart¹¹, Evgeny Belilovski⁵, José Cardoso-Landivar¹², Rosella Centis¹³, Lia D’Ambrosio¹⁴, Maria-Luiza De Souza-Galvão¹², Angel Dominguez-Castellano¹⁵, Samir Dourmane¹⁶, Mathilde Fréchet Jachym¹⁷, Antoine Froissart¹⁸, Vania Giacomet¹⁹, Delia Goletti²⁰, Soazic Grard²¹, Gina Gualano²², Armine Izadifar²³, Damien Le Du¹⁷, Margarita Marín Royo²⁴, Jessica Mazza-Stalder²⁵, Ilaria Motta²⁶, Catherine Wei Min Ong^{27,28}, Fabrizio Palmieri²², Frédéric Rivière²⁹, Teresa Rodrigo³, Denise Rossato Silva³⁰, Adrián Sánchez-Montalvá^{31,32,33}, Matteo Saporiti², Paolo Scarpellini³⁴, Frédéric Schlemmer³⁵, Antonio Spanevello^{36,37}, Elena Sumarokova⁵, Eva Tabernero³⁸, Paul Anantharajah Tambyah^{27,28}, Simon Tiberi^{39,40}, Alessandro Torre⁴¹, Dina Visca^{36,37}, Miguel Zabaleta Murguiondo⁴², Giovanni Sotgiu⁴³ and Giovanni Battista Migliori¹³

¹Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. ²TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy. ³Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain. ⁴Centre Hospitalier Universitaire, Nantes, France. ⁵Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation. ⁶The University of Sydney, Sydney Pharmacy School, Sydney, Australia. ⁷Westmead Hospital, Sydney, Australia. ⁸Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia. ⁹Service de Pneumologie CHU AMIENS PICARDIE, France AND UR Université de Picardie Jules Verne, Amiens, France. ¹⁰Service de Pneumologie, Clinique Saint Luc, Bouge, Belgium. ¹¹Dept of Internal Medicine, Lausanne University, Lausanne, Switzerland. ¹²Servicio Neumología, Vall D’Hebron University Hospital, Barcelona, Spain. ¹³Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy. ¹⁴Public Health Consulting Group, Lugano, Switzerland. ¹⁵Servicio de Enfermedades Infecciosas y Microbiología, Hospital Virgen Macarena, Sevilla, Spain. ¹⁶Service de Pneumologie, Groupe hospitalier sud île de France (GHSIF), Melun, France. ¹⁷Centre Hospitalier de Bligny, Briis Sous Forges, France. ¹⁸Service de Médecine interne, CHI de Créteil, Créteil, France. ¹⁹Pediatric Infectious Diseases Unit, Dept of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, Italy. ²⁰Translational Research Unit, National

Institute for Infectious Diseases ‘L. Spallanzani’, IRCCS, Rome, Italy. ²¹Centre de Lutte Antituberculeuse (CLAT 38), Grenoble, France. ²²Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases ‘L. Spallanzani’, IRCCS, Rome, Italy. ²³Hôpital Européen de Paris La Roseraie, Aubervilliers, France. ²⁴Servicio Neumología, Hospital General Universitario de Castellón, Castellón, Spain. ²⁵Pulmonary Division, Lausanne University Hospital CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ²⁶Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italia. ²⁷Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ²⁸Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore. ²⁹Hôpital d’Instruction des Armées (HIA) Percy, Clamart, France. ³⁰Faculdade de Medicina, Universidade Federal do Rio Grande do Sul – UFRGS, Porto Alegre, Brazil. ³¹Infectious Diseases Dept, International Health and Tuberculosis Unit, Vall d’Hebron University Hospital, Barcelona, Spain. ³²Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain. ³³Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain. ³⁴Unit of Infectious Diseases, Università Vita e Salute, San Raffaele Hospital, Milan, Italy. ³⁵Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France. ³⁶Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy. ³⁷Dept of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Italy. ³⁸Servicio Neumología, Hospital de Cruces, Bilbao, Spain. ³⁹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ⁴⁰Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK. ⁴¹Dept of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy. ⁴²Servicio Neumología Hospital Universitario Marqués de Valdecilla, Santander, Spain. ⁴³Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. ⁴⁴Co-first authors.

Correspondence: Giovanni Battista Migliori, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy. E-mail: giovannibattista.migliori@icsmaugeri.it

Received: 25 April 2020 | Accepted after revision: 10 May 2020

This article has an editorial commentary: <https://doi.org/10.1183/13993003.01348-2020>

Acknowledgements: The article is part of the scientific activities of the Global Tuberculosis Network (GTN); GREPI (Groupe de Recherche et d’Enseignement en Pneumo-Infectiologie), a working group from SPLF (Société de Pneumologie de Langue Française); SEPAR (Sociedad Española de Neumología and Cirugía Torácica); Moscow Society of Phthisiology and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020-GBM/RC/LDA). Delia Goletti is a professor of Pathology at Unicamillus University in Rome, Italy. The authors wish to thank Enrico Girardi (National Institute for Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy) for the useful comments on the manuscript.

Conflict of interest: None declared.

References

- 1 Worldometers. COVID-19 Coronavirus Pandemic. www.worldometers.info/coronavirus Date last updated: April 23, 2020.
- 2 Vitacca M, Nava S, Santus P, *et al.* Early consensus management for non-ICU ARF SARS-CoV-2 emergency in Italy: from ward to trenches. *Eur Respir J* 2020; 55: 2000632.
- 3 Lewis D. Is the coronavirus airborne? Experts can’t agree. *Nature* 2020; 580: 175.
- 4 Leung CC, Lam TH, Cheng KK. Let us not forget the mask in our attempts to stall the spread of COVID-19. *Int J Tuberc Lung Dis* 2020; 24: 364–366.
- 5 Esposito S, Principi N, Leung CC, *et al.* Universal use of face masks for success against COVID-19: evidence and implications for prevention policies. *Eur Respir J* 2020; 55: 2001260.
- 6 Guan WJ, Ni ZY, Hu Y, *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382: 1708–1720.
- 7 Xu XW, Wu XX, Jiang XG, *et al.* Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *BMJ* 2020; 368: m606.
- 8 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054–1062.
- 9 Noia Maciel EL, Gonçalves Júnior E, Pretti Dalcolmo MM. Tuberculosis and coronavirus: what do we know? *Epidemiol Serv Saúde* 2020; 29: e2020128.
- 10 Liu Y, Bi L, Chen Y, *et al.* Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. *MedRxiv* 2020; preprint [<https://doi.org/10.1101/2020.03.10.20033795>].
- 11 Singh A, Gupta A, Das K. Severe acute respiratory syndrome coronavirus-2 and pulmonary tuberculosis coinfection: double trouble. *Research Square* 2020; preprint [<https://doi.org/10.21203/rs.3.rs-22464/v1>].
- 12 Kim D, Quinn J, Pinsky B, *et al.* Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. *JAMA* 2020; 323: 2085–2086.
- 13 Borisov S, Danila E, Maryandyshev A, *et al.* Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. *Eur Respir J* 2019; 54: 1901522.
- 14 Akkerman O, Aleksa A, Alfenaar JW, *et al.* Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. *Int J Infect Dis* 2019; 83: 72–76.
- 15 Wen Z, Chi Y, Zhang L, *et al.* Coronavirus disease 2019: initial detection on chest CT in a retrospective multicenter study of 103 Chinese subjects. *Radiol Cardiothorac Imag* 2020; 2: e200092

Copyright ©ERS 2020.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.